Radiopharm Theranostics Limited (AU:RAD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Radiopharm Theranostics has successfully completed preclinical studies for its innovative prostate cancer treatment, RAD 402, showing promising safety and biodistribution results. The company plans to begin Phase I clinical trials in the second half of 2025, aiming to advance this next-generation radiotherapeutic to address unmet needs in advanced prostate cancer. This development signifies a potential breakthrough in cancer treatment, with RAD 402 targeting prostate-specific antigens using the novel isotope Terbium-161.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.